Literature DB >> 17011067

Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer.

Yoon Kyung Jeon1, Sook-Whan Sung, Jin-Haeng Chung, Weon-Seo Park, Jeong-Wook Seo, Chul Woo Kim, Doo Hyun Chung.   

Abstract

Increased epidermal growth factor receptor (EGFR) gene copy numbers and mutations predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). However, the clinicopathologic features of EGFR gene copy status in NSCLC remain unclear. We retrospectively analyzed 262 cases of NSCLC, including 135 squamous cell carcinomas (SCC) and 112 adenocarcinomas (ADC), for which paraffin blocks of the resected primary lung mass were available. None had received EGFR-targeted therapy. EGFR gene copy number was evaluated using fluorescence in situ hybridization (FISH), and EGFR expression was determined immunohistochemically using a tissue microarray. A high EGFR gene copy (EGFR FISH-positive) was found in 30.2% of the cases (amplification in 11.1% and high polysomy in 19.1%). There was no significant difference in EGFR FISH status with respect to SCC and ADC histology. The EGFR FISH-positive rate was higher in non-smokers than in smokers in the multivariate analysis (p=0.012). EGFR expression was significantly associated with a high EGFR gene copy and SCC histology (p=0.000). In the univariate survival analysis, EGFR FISH-positivity predicted worse survival in SCC (p=0.059), especially stage I SCC (p=0.04). EGFR amplification was associated with a shorter survival in node-positive SCC (p=0.015). However, the EGFR gene copy number or protein expression had no influence on the prognosis of ADC. In conclusion, the EGFR FISH-positive rate in Korean patients with NSCLC was similar to rates in Western populations, unlike the higher frequencies of EGFR mutation in East Asians. A high EGFR gene copy number was significantly more common in non-smokers, as were EGFR mutations. A high EGFR gene copy number predicted worse survival in SCC; therefore, the prognostic implications of the EGFR gene and protein should be analyzed in the context of histology and staging in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011067     DOI: 10.1016/j.lungcan.2006.08.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  29 in total

1.  ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.

Authors:  Mary Beth Beasley; Daniel T Milton
Journal:  J Oncol Pract       Date:  2011-04-25       Impact factor: 3.840

2.  Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.

Authors:  Yalei Zhang; Haihong Yang; Yuan Qiu; Qiuhua Deng; Jun Liu; Meiling Zhao; Ping He; Mingcong Mo; Xusen Zou; Jianxing He
Journal:  Med Oncol       Date:  2014-01-23       Impact factor: 3.064

3.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

Authors:  Jaemoon Koh; Heounjeong Go; Bhumsuk Keam; Moon-Young Kim; Soo Jeong Nam; Tae Min Kim; Se-Hoon Lee; Hye Sook Min; Young Tae Kim; Dong-Wan Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Mod Pathol       Date:  2015-07-17       Impact factor: 7.842

4.  The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.

Authors:  Chen Lin; Shanshan Wang; Weiwei Xie; Jianhua Chang; Yu Gan
Journal:  Cancer Biol Ther       Date:  2015-05-15       Impact factor: 4.742

5.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.

Authors:  Gillian Bethune; Drew Bethune; Neale Ridgway; Zhaolin Xu
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

6.  Targeted Therapies in Lung Cancer.

Authors:  Lucian R Chirieac; Sanja Dacic
Journal:  Surg Pathol Clin       Date:  2010-03-01

7.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

8.  Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.

Authors:  Zafer Cetin; Gulay Ozbilim; Abdullah Erdogan; Guven Luleci; Sibel Berker Karauzum
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

9.  Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

Authors:  Rikke Karlin Jepsen; Anne Guldhammer Skov; Birgit Guldhammer Skov
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

10.  Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

Authors:  Zhiyong Liang; Xuan Zeng; Jie Gao; Shafei Wu; Peng Wang; Xiaohua Shi; Jing Zhang; Tonghua Liu
Journal:  BMC Cancer       Date:  2008-12-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.